Skip to main content
Clinical Trials/NCT05103722
NCT05103722TerminatedNot Applicable

A Pilot Study of Combined Aerobic and Resistance Exercise Training in Metastatic Renal Cell Carcinoma

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins1 site in 1 country2 target enrollmentStarted: February 17, 2022Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Terminated
Enrollment
2
Locations
1
Primary Endpoint
Number of participants who adhere to the exercise intervention

Study Overview

Brief Summary

The trial studies the effects of personalized home-based aerobic and resistance exercises on quality of life, changes in physical activity levels, and the change in inflammatory myokines with the exercise intervention in Interleukin 6 (IL-6), C-reactive Protein (CRP), Leptin, Transforming growth factor beta (TGF-beta), and Interferon (INF) gamma.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Supportive Care
Masking
None

Eligibility Criteria

Ages
18 Years to 99 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Histologically confirmed diagnosis of RCC
  • •Patients being treated with standard of Programmed cell death protein 1 (anti-PD-1) or anti-PD-L1 immune-checkpoint inhibitor-containing standard of care regimen including patients who are about to start treatment or have been on treatment for a maximum of 4 weeks prior to signing consent
  • •Metastatic Measurable disease, as defined by RECIST 1.1
  • •Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 with a life expectancy ≥ six months
  • •Physically able to enroll in the exercise program as determined by the treating medical oncologist and after review by Physical medicine and rehabilitation physicians at Johns Hopkins
  • •Adequate bone marrow reserve and organ function measured within 28 days prior to administration of study treatment with the following key parameters:
  • •Hematological:
  • •Absolute neutrophil count ≥ 1.5 × 109/L
  • •Platelets ≥ 100 × 109/L
  • •Hemoglobin≥ 9.0 g/dL
  • •Serum Creatinine ≤ 1.5 x the upper limit of normal (ULN) or Calculated Creatinine clearance ≥ 30mL/min
  • •Total bilirubin ≤ 1.5 x ULN (Patients with known Gilbert disease who have serum bilirubin level ≤ 3 x ULN may be enrolled)
  • •Serum Aspartate aminotransferase (AST) and serum Alanine aminotransferase (ALT) ≤ 2.5 x ULN (For patients with documented liver metastases AST and/or ALT ≤ 5 x ULN)

Exclusion Criteria

  • •The presence of bone metastasis in the spine, pelvis, and lower limbs
  • •Currently physically active or moderately active as determined by Leisure Score Index of Godin Leisure-Time Exercise Questionnaire (GSLTPAQ)
  • •History of underlying cardiovascular, respiratory, musculoskeletal disease or joint problems that preclude moderate physical activity
  • •Known underlying uncontrolled brain metastatic lesions requires steroids therapy and/or radiotherapy
  • •Major surgery within four weeks prior to enrollment.
  • •Radiotherapy for RCC 28 days prior to week 1 day 1

Arms & Interventions

Supportive Care

Experimental

Patients with metastatic renal cell carcinoma (RCC) who are receiving immune-checkpoint inhibitor therapy

Intervention: Combined Aerobic and Resistance Exercise Training (Other)

Outcomes

Primary Outcomes

Number of participants who adhere to the exercise intervention

Time Frame: 2 years

Secondary Outcomes

  • The incidence of grade 3-5 toxicities as per CTCAE 5.0(2 years)
  • Change in HRQoL as measured by FACT-G Questionnaire(Baseline, Week 4, Week 8, Week 12 and Week 24)
  • Percentage of patients who remained in the study and didn't drop off the study after enrollment(2 years)
  • Percentage of patients screened compared to patients enrolled(2 years)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials